Methotrexate Tablets

Be fully familiar with this drug's toxicity before use. Obtain baseline and monitor CBCs for myelosuppression, and hepatic, renal and pulmonary function; reduce dose, interrupt, or discontinue if needed. Monitor for neurotoxicity, dermatologic toxicity. Avoid excessive sun exposure. Increased risk of serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor and treat promptly. Peptic ulcer disease. Ulcerative colitis. Increased risk of hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g). Update immunizations according to current guidelines prior to initiation. Permanently discontinue if anaphylaxis, other serious hypersensitivity or severe dermatologic reactions occur. Evacuate significant third-space accumulations prior to administration. Renal or hepatic impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Be fully familiar with this drug's toxicity before use. Obtain baseline and monitor CBCs for myelosuppression, and hepatic, renal and pulmonary function; reduce dose, interrupt, or discontinue if needed. Monitor for neurotoxicity, dermatologic toxicity. Avoid excessive sun exposure. Increased risk of serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor and treat promptly. Peptic ulcer disease. Ulcerative colitis. Increased risk of hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g). Update immunizations according to current guidelines prior to initiation. Permanently discontinue if anaphylaxis, other serious hypersensitivity or severe dermatologic reactions occur. Evacuate significant third-space accumulations prior to administration. Renal or hepatic impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Be fully familiar with this drug's toxicity before use. Obtain baseline and monitor CBCs for myelosuppression, and hepatic, renal and pulmonary function; reduce dose, interrupt, or discontinue if needed. Monitor for neurotoxicity, dermatologic toxicity. Avoid excessive sun exposure. Increased risk of serious infections (eg, bacterial, fungal, viral) including opportunistic infections; monitor and treat promptly. Peptic ulcer disease. Ulcerative colitis. Increased risk of hepatotoxicity with alcoholism or receiving total cumulative dose (≥1.5g). Update immunizations according to current guidelines prior to initiation. Permanently discontinue if anaphylaxis, other serious hypersensitivity or severe dermatologic reactions occur. Evacuate significant third-space accumulations prior to administration. Renal or hepatic impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).